title: Cytomegalovirus DNAemia detected with real-time polymerase chain reaction in hematopoietic stem cell transplant patients.
abstract: BACKGROUND
  Cytomegalovirus (CMV) infections continue to cause significant morbidity and mortality in hematopoietic stem cell transplant (HSCT) recipients. Successful pre-emptive therapy in transplant patients depends on the availability of reliable diagnostic tests for CMV infections. The purpose of this retrospective study was to evaluate CMV DNA viral load, incidence of CMV disease and CMV seropositivity, risk factors and correlation between CMV DNA positivity and clinical course in HSCT patients.
  
  
  METHODS
  Two hundred and twenty-five patients who underwent peripheral blood stem cell or bone marrow transplantation between June 2003 and April 2010 were included. A real-time polymerase chain reaction (RT-PCR) assay was used for CMV monitoring.
  
  
  RESULTS
  Recipient median age was 42.5 years. CMV seropositivity was 95.6%. CMV DNA positivity determined by RT-PCR was 24.9% among the entire patient group. CMV DNA positivity with RT-PCR was found to be significantly higher in allogeneic transplant recipients than autologous transplant recipients (46.7% vs 14.0%; P < 0.0001). Gender, age, conditioning regimen, stem cell source, underlying disease and recipient and donor seropositivity (alone or paired) were not significant risk factors for CMV DNAemia. We did not observe any CMV end-organ disease.
  
  
  CONCLUSIONS
  CMV DNAemia was significantly higher in allogeneic transplant recipients than in autologous transplant patients. End-organ disease could be prevented with appropriate pre-emptive therapy.
authors: Deniz Goren
authors: DG
authors: Sahin
authors: Eren
authors: E
authors: Gunduz
authors: Nilgun
authors: N
authors: Kasifoglu
authors: Olga Meltem
authors: OM
authors: Akay
authors: Tercan
authors: T
authors: Us
authors: Zafer
authors: Z
authors: Gulbas
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use; D015331:Cohort Studies; D003587:Cytomegalovirus / Q000235:genetics*; D003586:Cytomegalovirus Infections / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy; D004279:DNA, Viral / Q000097:blood*; D061345:Early Medical Intervention; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016015:Logistic Models; D008232:Lymphoproliferative Disorders / Q000150:complications / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D060888:Real-Time Polymerase Chain Reaction; D012189:Retrospective Studies; D012307:Risk Factors; D012698:Serologic Tests; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous; D019562:Viral Load; D014766:Viremia / Q000175:diagnosis*; D055815:Young Adult
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral